Loading
Neuraxis, Inc Stock: price and insider trades · United States
3 insiders bought €11k of shares over the last 90 days, the latest by Carrico Brian Allen, filed 08 Oct 2026.
Cluster: 3 buyers in 30 daysNeuraxis, Inc: what insiders have been doing
Every trade that managers of Neuraxis, Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 22 October 2026, 24 filings were filed, from 9 insiders.
Only purchases show up on the open market, 9 purchases in all worth €1.2M, filed by 5 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Aharon Gil filed the largest purchase, €856k, on 29 December 2025. The buyers include 2 senior executives, 1 major shareholder and 1 finance chief.
For context, the typical company on the same exchange (median of 2,023 companies) published 41 filings over the same period, against 24 filings here. Over the whole record (from 2023), the tally stands at 11 purchases and 3 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 3.6 m USD and net income at -7.8 m USD.
In the case of 6 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase is recent: it was published 16 days ago, on 8 October 2026. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
41
Thresholds
n/a
Buy Volume
€2M
11 ops. · all time
Sell Volume
€2M
3 ops. · all time
Who traded when
BuySaleBrian Hannasch4 buys
Brian Allen Carrico2 buys
Masimo Corp2 sales
Thomas Joeseph Carrico2 buys
Timothy Robert Henrichs2 buys
Gil Aharon1 buy
Since the insiders bought
- +6.0%Entry US$7.41 · Close 19 Oct 2026 US$7.86
- +6.0%Entry US$7.41 · Close 19 Oct 2026 US$7.86
- +6.0%Entry US$7.41 · Close 19 Oct 2026 US$7.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Neuraxis, Inc Strong Buy (bullish), based on 2 analysts. Average price target: US$11.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,098 of 26,250 companies
33.2
score / 100
Value19
Quality48
FCF yld-6.7%
Earn yld-8.8%
EV/EBITDA·
ROE-140%
Gross mgn84%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.82
Analyst consensus
2 analystsStrong buy
US$9.00Target US$11.00(+41%)US$13.00
Income statement
RevenueUS$3.6M
Gross profitUS$3M84% margin
EBITDA-US$7.7M-215% margin
Net income-US$8.6M-144.4% margin
Valuation
PER (forward)-29.0x
P/Book14.5x
Beta1.37
Balance sheet & cash
Market capUS$98.2M
Total debtUS$416.6k
Free Cash Flow-US$6.6M
Debt / Equity4%
Profitability & ownership
ROE-139.8%
ROA-56.2%
% insiders25.4%
% institutions28.4%
Last declaration on 8 October 2026
Declarations41 total
268 shares@ US$4.840.0015% mcap7.8% of flowCommon StockSEC:0001493152-26-046382:0
Canonical exit: 6 Jan 2027 (T+90)
328 shares@ US$4.840.0019% mcap55.7% of flowCommon StockSEC:0001493152-26-046381:0
Canonical exit: 6 Jan 2027 (T+90)
1,937 shares@ US$4.840.011% mcap39.5% of flowCommon StockSEC:0001493152-26-046380:0
Canonical exit: 6 Jan 2027 (T+90)
199,188 sharesCommon StockSEC:0001493152-26-040274:0
193,678 sharesCommon StockSEC:0001493152-26-040275:0
199,106 sharesCommon StockSEC:0001493152-26-040276:0
2,226 sharesCommon StockSEC:0001493152-26-038815:0
40,068 sharesCommon StockSEC:0001493152-26-038815:2
31,134 shares@ US$6.280.20% mcap58.1% of flowCommon StockSEC:0001493152-26-038821:0
43,930 shares@ US$6.280.29% mcap20.3% of flowCommon StockSEC:0001493152-26-038815:1
26,073 shares@ US$6.280.17% mcap53.8% of flowCommon StockSEC:0001493152-26-038827:0
26,073 shares@ US$6.280.17% mcap53.8% of flowCommon StockSEC:0001493152-26-038831:0
12,304 sharesCommon StockSEC:0001493152-26-020778:0
221,917 sharesCommon StockSEC:0001493152-26-020778:1
8,060 shares@ US$1.96100.0% of flowCommon StockSEC:0001493152-26-015069:0
Canonical exit: 30 Jun 2026 (T+90)
667 shares@ US$1.96100.0% of flowCommon StockSEC:0001493152-26-015071:0
Canonical exit: 30 Jun 2026 (T+90)
7,593 shares@ US$1.96100.0% of flowCommon StockSEC:0001493152-26-015073:0
Canonical exit: 30 Jun 2026 (T+90)
21,598 shares@ US$4.6332.4% of flowCommon StockSEC:0001493152-26-008235:0
21,598 shares@ US$4.6332.4% of flowCommon StockSEC:0001493152-26-008234:0
40,000 shares@ US$4.9216.1% of flowCommon StockSEC:0001437749-26-004101:1
Canonical exit: 13 May 2026 (T+90)
40,000 shares@ US$4.6518.2% of flowCommon StockSEC:0001437749-26-004101:0
Canonical exit: 12 May 2026 (T+90)
21,598 shares@ US$4.6329.4% of flowCommon StockSEC:0001493152-26-004588:0
21,598 shares@ US$4.637.3% of flowCommon SharesSEC:0001493152-26-004590:0
286,138 shares@ US$3.5272.5% of flowCommon SharesSEC:0001811824-25-000002:0
Canonical exit: 23 Mar 2026 (T+90)
13,157 shares@ US$2.8513.8% of flowCommon StockSEC:0001641172-25-027023:0
25 of 41 declarations
About Neuraxis, Inc
Neuraxis, Inc is a company listed on the XNAS market. It specializes in developing innovative solutions in the healthcare sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
